BACKGROUND: We previously reported that eradication of Helicobacter pylori in our cohort of patients with peptic ulcer disease reduced their risk of developing gastric cancer to approximately one-third after a mean follow-up period of 3.4 years (up to 8.6 years). We have now followed these patients for a longer period. METHODS: A total of 1,222 consecutive patients with peptic ulcer diseases who completed more than 1-year follow-up after receiving H. pylori eradication therapy were followed with annual endoscopic surveillance for a mean of 9.9 years (as long as 17.4 years). RESULTS: H. pylori infection was judged cured in 1,030 patients (eradication-success group) but persisted in 192 (eradication-failure group) after initial eradication therapy. In the eradication-failure group, 114 patients received re-treatment at a mean of 4.4 years after the start of follow-up, and 105 of these were cured of infection. Gastric cancer developed in 21 of the 1,030 patients in the eradication-success group and in nine of the 192 in the failure group (p = 0.04). The risk of developing gastric cancer in the eradication-success group (0.21 %/year) was significantly lower than that in the failure group (0.45 %, p = 0.049). The longest interval between the initial H. pylori eradication and the occurrence of gastric cancer was 14.5 years in the eradication-success group and 13.7 years in the eradication-failure group. CONCLUSIONS: A prophylactic effect for gastric cancer persists for more than 10 years after H. pylori eradication therapy, but we should be aware that cancer can develop even after that interval.
BACKGROUND: We previously reported that eradication of Helicobacter pylori in our cohort of patients with peptic ulcer disease reduced their risk of developing gastric cancer to approximately one-third after a mean follow-up period of 3.4 years (up to 8.6 years). We have now followed these patients for a longer period. METHODS: A total of 1,222 consecutive patients with peptic ulcer diseases who completed more than 1-year follow-up after receiving H. pylori eradication therapy were followed with annual endoscopic surveillance for a mean of 9.9 years (as long as 17.4 years). RESULTS:H. pyloriinfection was judged cured in 1,030 patients (eradication-success group) but persisted in 192 (eradication-failure group) after initial eradication therapy. In the eradication-failure group, 114 patients received re-treatment at a mean of 4.4 years after the start of follow-up, and 105 of these were cured of infection. Gastric cancer developed in 21 of the 1,030 patients in the eradication-success group and in nine of the 192 in the failure group (p = 0.04). The risk of developing gastric cancer in the eradication-success group (0.21 %/year) was significantly lower than that in the failure group (0.45 %, p = 0.049). The longest interval between the initial H. pylori eradication and the occurrence of gastric cancer was 14.5 years in the eradication-success group and 13.7 years in the eradication-failure group. CONCLUSIONS: A prophylactic effect for gastric cancer persists for more than 10 years after H. pylori eradication therapy, but we should be aware that cancer can develop even after that interval.
Authors: S Ito; T Azuma; H Murakita; M Hirai; H Miyaji; Y Ito; Y Ohtaki; Y Yamazaki; M Kuriyama; Y Keida; Y Kohli Journal: Gut Date: 1996-12 Impact factor: 23.059
Authors: N Sakaki; T Arakawa; H Katou; K Momma; N Egawa; T Kamisawa; Y Yamada; Y Tu; C Ishikawa; J Ishiwata Journal: J Gastroenterol Date: 1997-02 Impact factor: 7.527
Authors: K Satoh; K Kimura; Y Taniguchi; Y Yoshida; K Kihira; T Takimoto; H Kawata; K Saifuku; K Ido; T Takemoto; Y Ota; M Tada; M Karita; N Sakaki; Y Hoshihara Journal: Am J Gastroenterol Date: 1996-05 Impact factor: 10.864
Authors: Andrea L Matthis; Izumi Kaji; Kristen A Engevik; Yasutada Akiba; Jonathan D Kaunitz; Marshall H Montrose; Eitaro Aihara Journal: Dig Dis Sci Date: 2019-09-12 Impact factor: 3.199